| DC7362 |
AT13148
Featured
|
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor. |
|
| DC20698 |
AT-403 |
AT-403 (AT403) is a potent, highly selective, nonpeptide NOP agonist with pEC50 of 9.45. |
|
| DC7363 |
AT-406
Featured
|
AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively. |
|
| DC23554 |
AT791 |
AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro. |
|
| DC21122 |
Ataciguat sodium |
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
|
| DC21121 |
Ataciguat
Featured
|
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
|
| DC23606 |
Atagabalin |
Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.. |
|
| DC7365 |
ATB-346
Featured
|
ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity. |
|
| DC7366 |
Atglistatin
Featured
|
Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM. |
|
| DC21656 |
Atiprimod |
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
|
| DC21657 |
Atiprimod dihydrochloride |
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
|
| DC20033 |
ATM Inhibitor-1 |
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0 |
|
| DC12627 |
ATM-3507 |
ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM. |
|
| DC7709 |
ATN-161
Featured
|
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
|
| DCAPI1522 |
Atocalcitol |
Atocalcitol |
|
| DC23607 |
Atomoxetine |
Atomoxetine ((R)-Tomoxetine. |
|
| DCAPI1390 |
Atovaquone (Atavaquone)
Featured
|
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. |
|
| DCAPI1401 |
ATP (Adenosine-Triphosphate) |
ATP (Adenosine-Triphosphate) |
|
| DC11095 |
ATR-101 free base |
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
|
| DC22775 |
ATR-101 |
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
|
| DC23072 |
Atractylenolide II
Featured
|
Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effe |
|
| DC23073 |
Atractylenolide III
Featured
|
Atractylenolide III, a potential house dust mite control agent, has neuroprotection, gastroprotective, anti-cancer, and anti-inflammatory activities, it also may control immunological reactions by regulating the cellular functions of IL-6 in mast cells. |
|
| DC23059 |
Atractylon
Featured
|
Atractylone has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions. |
|
| DCAPI1288 |
Atracurium besylate
Featured
|
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. |
|
| DC22004 |
ATV399 |
ATV399 (ATV-399) is a novel small molecule that dose-dependently reduces the cleaved caspase9 levels with IC50 of 3.3 uM, inhibits dimerization of iNOS. |
|
| DC20114 |
ATWLPPR Peptide TFA |
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes. |
|
| DC23401 |
AU1 |
AU1 (GSK 1379725A) is the first selective small molecule inhibitor of BPTF bromodomain (bromodomain PHD finger transcription factor) with Kd of 2.8 uM in a cell-based reporter assay, shows no binding activity for Brd4. |
|
| DC21865 |
Aumitin
Featured
|
Aumitin is a novel potent autophagy inhibitor with IC50 of 124 and 244 nM against starvation- and rapamycin- induced autophagy respectively, targets mitochondrial complex I. |
|
| DC12428 |
AUNP-12
Featured
|
AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide, blocks the PD-1/PD-L1, PD-1/PD-L2 and PD-L1/CD80 pathways. |
|
| DC26036 |
Aurantiamide acetate |
Aurantiamide acetate suppresses the growth of malignant gliomas in vitro and in vivo by inhibiting autophagic flux. |
|
